Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial Journal Article
| Authors: | Raza, A.; Jurcic, J. G.; Roboz, G. J.; Maris, M.; Stephenson, J. J.; Wood, B. L.; Feldman, E. J.; Galili, N.; Grove, L. E.; Drachman, J. G.; Sievers, E. L. |
| Article Title: | Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial |
| Abstract: | A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and prolonged duration of treatment for responding patients were evaluated. Over the dose range of 1.5-8 mg/kg/week, lintuzumab was well tolerated, and a maximum tolerated dose was not defined. The most common adverse event was transient chills with the initial lintuzumab infusion (39%). Responses were observed in 7 of 17 patients with acute myeloid leukemia: morphologic complete remission (n = 4), partial remission (n = 2), and morphologic leukemia-free state (n = 1). Of 14 patients with myelodysplastic syndrome or myeloproliferative diseases, 1 patient had major hematologic improvement and 9 patients had stable disease. In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity. |
| Keywords: | myeloproliferative disorders; transplantation; response criteria; retinoic acid; therapy; gemtuzumab ozogamicin; cells; induction; progenitor; antibody-based immunotherapy; myeloid leukemias and dysplasias; anti-cd33 monoclonal-antibody; international working group; stem-cell; hum195 |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 50 |
| Issue: | 8 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-01-01 |
| Start Page: | 1336 |
| End Page: | 1344 |
| Language: | English |
| ACCESSION: | ISI:000268825900015 |
| DOI: | 10.1080/10428190903050013 |
| PROVIDER: | wos |
| Notes: | --- - Article - "Source: Wos" |
